- January 09-13, 2017
J.P. Morgan 35th Annual Healthcare Conference, San Francisco, California
- February 20-22, 2017
2nd Annual Cancer Immunotherapy Conference, part of 24th International Molecular Medicine Tri-Conference, San Francisco, California.
On February 20 between 12:00 pm and 12:30 pm, Frederic Triebel will present pre-clinical results for the anti-PD-1/IMP321 combination and TACTI-mel trial design with the topic “TACTI-mel, Two ACTive Immunotherapies in Melanoma: Combination of IMP321 (LAG-3Ig) with an Anti-PD-1 Antagonist in a Phase I Trial".
- March, 7-8, 2017
Breast Cancer Summit, Boston, Massachusetts.
On March 7, Frederic Triebel will talk about "An active immunotherapy combined with first-line weekly paclitaxel in metastatic breast cancer: first results of IMP321 (LAG-3Ig) as an antigen presenting cell activator in the AIPAC phase IIb trial."
- March 14-16, 2017
3rd Annual Immune Checkpoint Inhibitors (ICI) Boston conference, Massachusetts
- March 28th, 2017
5th Annual Cancer BioPartnering & Investment Forum, New York Academy of Sciences, New York City, New Jersey
- June 02-06, 2017
ASCO 2017, Chicago, Illinois